Arbutus Biopharma Cp (ABUS)

$3.06 -0.08 (-2.55%)
Market Cap 592.57M
Revenue (ttm) 18.14M
Net Income (ttm) -72.85M
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 649,900
Avg Vol 936,122
Day's Range N/A - N/A
Shares Out 188.72M
Stochastic %K 2%
Beta 1.98
Analysts Strong Sell
Price Target $4.50

Company Profile

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 1 and phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the poten...

Industry: Biotechnology
Sector: Healthcare
Phone: 267 469 0914
Address:
701 Veterans Circle, Warminster, United States
Heavey
Heavey Jan. 14 at 12:21 PM
$ABUS no temptation to sell whatsoever. Loving silver’s run 🤑
0 · Reply
Theverypatientone
Theverypatientone Jan. 14 at 2:35 AM
$ABUS - as i have said before Pfe/BNTX will settle first and $MRNA will become hostile takeover target. Acuitas is a no factor, will cease to exist. Bought also 5k more of $ALT BIC in MASH. Abus long and strong
1 · Reply
Alfalcon
Alfalcon Jan. 13 at 8:33 PM
$ABUS Any guessimates how quickly phizer will settle post moderna judgement? Gline opined at JPM that he views as separate and distinct case merits.
3 · Reply
Nile1
Nile1 Jan. 13 at 8:09 PM
$ABUS I will definitely take 1:1 share swap with $MRNA
2 · Reply
anthonydabbraccio
anthonydabbraccio Jan. 13 at 8:09 PM
$ABUS moderna crushing it 15 percent right now, where is our 15?
0 · Reply
Heavey
Heavey Jan. 13 at 7:53 PM
$ABUS remember “Fib a bit”, they’re goners! Makes Jury’s decision easy! No settlement for me. Will be 5 years of pain, gone.
1 · Reply
Grtgooglymoogly
Grtgooglymoogly Jan. 13 at 7:38 PM
$ABUS The price increase must be the Zacks upgrade. 😁🙄....They must have been really working the 🎱 or 🔮.
0 · Reply
SpaceCityKid
SpaceCityKid Jan. 13 at 7:23 PM
$ABUS ROIV breaks to a new ATH. Something's brewing
0 · Reply
renoH4
renoH4 Jan. 13 at 6:44 PM
$ABUS ..imo Moderna is interested in a high share price of their own shares to settle with a share switch 1 for 2 or 3 or.. in the next 2 weeks. They have to offer it and the shareholders have to accept it. Time needed : minimum 4 - 6 weeks to close the process after announcement - so they must act in January. Will we see a trading halt for some weeks ?
1 · Reply
Alfalcon
Alfalcon Jan. 13 at 5:12 PM
$ABUS Defendants ticker been preparing for judgement day! And crash. 30-40-50%
0 · Reply
Latest News on ABUS
Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 13, 2025, 7:30 AM EST - 2 months ago

Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025

Oct 7, 2025, 8:00 AM EDT - 3 months ago

Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025

Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 6, 2025, 7:30 AM EDT - 5 months ago

Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus

Jun 25, 2025, 7:30 AM EDT - 7 months ago

Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus

Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 14, 2025, 7:30 AM EDT - 8 months ago

Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update

Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025

May 7, 2025, 2:01 AM EDT - 9 months ago

Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025

Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025

Apr 23, 2025, 2:01 AM EDT - 9 months ago

Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025

Arbutus Biopharma Cuts Workforce by More Than Half, Hires New CFO in Exec Shuffle

Mar 27, 2025, 7:56 AM EDT - 10 months ago

Arbutus Biopharma Cuts Workforce by More Than Half, Hires New CFO in Exec Shuffle

Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update

Mar 27, 2025, 7:30 AM EDT - 10 months ago

Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update

Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna

Mar 3, 2025, 9:15 AM EST - 11 months ago

Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna

ROIV

Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO

Feb 25, 2025, 7:00 AM EST - 11 months ago

Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO

Arbutus, Burford Capital, And Cadiz With Chris DeMuth Jr.

Jan 30, 2025, 3:40 PM EST - 1 year ago

Arbutus, Burford Capital, And Cadiz With Chris DeMuth Jr.

BUR CDZI

Arbutus Provides 2025 Corporate and Financial Update

Jan 13, 2025, 7:30 AM EST - 1 year ago

Arbutus Provides 2025 Corporate and Financial Update

Arbutus: Positive Imdusiran Data Leads To Phase 2B Development

Jan 7, 2025, 7:56 AM EST - 1 year ago

Arbutus: Positive Imdusiran Data Leads To Phase 2B Development

Whitefort Capital Sends Letter to Arbutus Biopharma Board of Directors

Dec 3, 2024, 8:00 AM EST - 1 year ago

Whitefort Capital Sends Letter to Arbutus Biopharma Board of Directors

Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat

Nov 26, 2024, 7:30 AM EST - 1 year ago

Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat

Arbutus' Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon

Nov 15, 2024, 11:02 AM EST - 1 year ago

Arbutus' Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon

Arbutus to Present at Jefferies London Healthcare Conference

Nov 14, 2024, 7:30 AM EST - 1 year ago

Arbutus to Present at Jefferies London Healthcare Conference

Arbutus Biopharma Corporation (ABUS) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 2:52 PM EST - 1 year ago

Arbutus Biopharma Corporation (ABUS) Q3 2024 Earnings Call Transcript

Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update

Oct 23, 2024, 7:30 AM EDT - 1 year ago

Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update

Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting® 2024

Oct 15, 2024, 8:16 AM EDT - 1 year ago

Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting® 2024

Arbutus to Participate in Two Upcoming Investor Conferences

Sep 3, 2024, 7:30 AM EDT - 1 year ago

Arbutus to Participate in Two Upcoming Investor Conferences

Arbutus Biopharma Corporation (ABUS) Q2 2024 Earnings Call Transcript

Aug 1, 2024, 2:00 PM EDT - 1 year ago

Arbutus Biopharma Corporation (ABUS) Q2 2024 Earnings Call Transcript

Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 1, 2024, 7:30 AM EDT - 1 year ago

Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Arbutus to Report Second Quarter 2024 Financial Results and Provide Corporate Update

Jul 18, 2024, 7:30 AM EDT - 1 year ago

Arbutus to Report Second Quarter 2024 Financial Results and Provide Corporate Update

Arbutus Biopharma's IP Legal Wins And Clinical Trials - A Strong Buy Opportunity

Jul 5, 2024, 5:29 AM EDT - 1 year ago

Arbutus Biopharma's IP Legal Wins And Clinical Trials - A Strong Buy Opportunity

Treatment with Arbutus' Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels

Jun 6, 2024, 11:15 AM EDT - 1 year ago

Treatment with Arbutus' Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels

Arbutus' Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure

Jun 5, 2024, 2:30 AM EDT - 1 year ago

Arbutus' Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure

Arbutus Distributors Ltd. News Release

Jun 3, 2024, 9:50 AM EDT - 1 year ago

Arbutus Distributors Ltd. News Release

Arbutus to Participate in Jefferies Global Healthcare Conference

May 29, 2024, 7:30 AM EDT - 1 year ago

Arbutus to Participate in Jefferies Global Healthcare Conference

Arbutus to Present Imdusiran Data at EASL Congress 2024

May 22, 2024, 2:00 AM EDT - 1 year ago

Arbutus to Present Imdusiran Data at EASL Congress 2024

Whitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders Outlining Paths to Maximize Value

May 17, 2024, 9:00 AM EDT - 1 year ago

Whitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders Outlining Paths to Maximize Value

Arbutus Biopharma Corporation (ABUS) Q1 2024 Earnings Call Transcript

May 2, 2024, 1:15 PM EDT - 1 year ago

Arbutus Biopharma Corporation (ABUS) Q1 2024 Earnings Call Transcript

Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 2, 2024, 7:30 AM EDT - 1 year ago

Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update

Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024

May 2, 2024, 7:25 AM EDT - 1 year ago

Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024

Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update

Apr 18, 2024, 7:30 AM EDT - 1 year ago

Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update

Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna

Apr 4, 2024, 8:30 AM EDT - 1 year ago

Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna

Arbutus Biopharma Corporation (ABUS) Q4 2023 Earnings Call Transcript

Feb 29, 2024, 1:05 PM EST - 2 years ago

Arbutus Biopharma Corporation (ABUS) Q4 2023 Earnings Call Transcript

Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update

Feb 29, 2024, 7:30 AM EST - 2 years ago

Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update

Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update

Feb 15, 2024, 7:30 AM EST - 2 years ago

Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update

Arbutus Announces 2024 Corporate Objectives and Provides Financial Update

Jan 8, 2024, 7:30 AM EST - 2 years ago

Arbutus Announces 2024 Corporate Objectives and Provides Financial Update

Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting®

Nov 9, 2023, 4:01 PM EST - 2 years ago

Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting®

Arbutus Biopharma Corporation (ABUS) Q3 2023 Earnings Call Transcript

Nov 7, 2023, 11:06 AM EST - 2 years ago

Arbutus Biopharma Corporation (ABUS) Q3 2023 Earnings Call Transcript

Arbutus Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 7, 2023, 7:30 AM EST - 2 years ago

Arbutus Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Arbutus Announces CEO, William Collier, to Retire December 31, 2023

Nov 7, 2023, 7:15 AM EST - 2 years ago

Arbutus Announces CEO, William Collier, to Retire December 31, 2023

Arbutus to Report Third Quarter 2023 Financial Results and Provide Corporate Update

Oct 24, 2023, 7:30 AM EDT - 2 years ago

Arbutus to Report Third Quarter 2023 Financial Results and Provide Corporate Update

Arbutus to Present at H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Virtual Conference

Oct 18, 2023, 7:30 AM EDT - 2 years ago

Arbutus to Present at H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Virtual Conference

Arbutus Announces Multiple Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2023

Oct 11, 2023, 8:05 AM EDT - 2 years ago

Arbutus Announces Multiple Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2023

Arbutus Announces Pipeline Updates and Dosing of the First Subject in the Phase 1a/1b Clinical Trial with AB-101; Cash Runway Extended

Sep 11, 2023, 4:15 PM EDT - 2 years ago

Arbutus Announces Pipeline Updates and Dosing of the First Subject in the Phase 1a/1b Clinical Trial with AB-101; Cash Runway Extended

Arbutus Reports Second Quarter 2023 Financial Results and Corporate Update

Aug 3, 2023, 7:30 AM EDT - 2 years ago

Arbutus Reports Second Quarter 2023 Financial Results and Corporate Update

Heavey
Heavey Jan. 14 at 12:21 PM
$ABUS no temptation to sell whatsoever. Loving silver’s run 🤑
0 · Reply
Theverypatientone
Theverypatientone Jan. 14 at 2:35 AM
$ABUS - as i have said before Pfe/BNTX will settle first and $MRNA will become hostile takeover target. Acuitas is a no factor, will cease to exist. Bought also 5k more of $ALT BIC in MASH. Abus long and strong
1 · Reply
Alfalcon
Alfalcon Jan. 13 at 8:33 PM
$ABUS Any guessimates how quickly phizer will settle post moderna judgement? Gline opined at JPM that he views as separate and distinct case merits.
3 · Reply
Nile1
Nile1 Jan. 13 at 8:09 PM
$ABUS I will definitely take 1:1 share swap with $MRNA
2 · Reply
anthonydabbraccio
anthonydabbraccio Jan. 13 at 8:09 PM
$ABUS moderna crushing it 15 percent right now, where is our 15?
0 · Reply
Heavey
Heavey Jan. 13 at 7:53 PM
$ABUS remember “Fib a bit”, they’re goners! Makes Jury’s decision easy! No settlement for me. Will be 5 years of pain, gone.
1 · Reply
Grtgooglymoogly
Grtgooglymoogly Jan. 13 at 7:38 PM
$ABUS The price increase must be the Zacks upgrade. 😁🙄....They must have been really working the 🎱 or 🔮.
0 · Reply
SpaceCityKid
SpaceCityKid Jan. 13 at 7:23 PM
$ABUS ROIV breaks to a new ATH. Something's brewing
0 · Reply
renoH4
renoH4 Jan. 13 at 6:44 PM
$ABUS ..imo Moderna is interested in a high share price of their own shares to settle with a share switch 1 for 2 or 3 or.. in the next 2 weeks. They have to offer it and the shareholders have to accept it. Time needed : minimum 4 - 6 weeks to close the process after announcement - so they must act in January. Will we see a trading halt for some weeks ?
1 · Reply
Alfalcon
Alfalcon Jan. 13 at 5:12 PM
$ABUS Defendants ticker been preparing for judgement day! And crash. 30-40-50%
0 · Reply
DocPharm
DocPharm Jan. 13 at 4:55 PM
$ABUS food for thought - Zero ABUS presentations to shareholders since the quiet period announcement Only presentation has been regarding Genevant at $ROIV R&D day Very little communication to SH since - Only those required by law Reminder $ROIV overhauled the Exec team and BoD last year
1 · Reply
MoneyGroupLLC
MoneyGroupLLC Jan. 13 at 4:50 PM
Enter: $ABUS Calls Strike Price: $5 Expiry Date: FEB 20 2026 Buy in Price: $0.40 - $0.45 Sell Price: $0.77 Profit : +70% (Turn every $1 into $1.70) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/
0 · Reply
Shortsales
Shortsales Jan. 13 at 4:35 PM
$ABUS
1 · Reply
Planetpaprika
Planetpaprika Jan. 13 at 1:45 PM
$ABUS Moderna is on a minefield... https://business.times-online.com/times-online/article/marketminute-2026-1-12-the-mrna-pivot-moderna-navigates-regulatory-headwinds-and-tariff-turmoil-in-a-volatile-2026-biotech-landscape
1 · Reply
tommydoc
tommydoc Jan. 12 at 11:30 PM
$ABUS Those who stay will be champions! Not much more to say!
0 · Reply
Jdvm
Jdvm Jan. 12 at 10:54 PM
$ABUS
1 · Reply
Thepatientone
Thepatientone Jan. 12 at 10:26 PM
$ABUS We are owed a damn update. This was a year ago.
4 · Reply
Buqqets
Buqqets Jan. 12 at 10:09 PM
$ABUS games being played here are comical, to say the least.
0 · Reply
Intergalactic_Portfolio
Intergalactic_Portfolio Jan. 12 at 10:00 PM
$ABUS Usual low vol Happy Meal money after hours tape painting?
0 · Reply
Grtgooglymoogly
Grtgooglymoogly Jan. 12 at 9:15 PM
$ABUS Short interest jumped up about 1,800,000 shares as of Dec. 31st..
1 · Reply
Heavey
Heavey Jan. 12 at 8:26 PM
$ABUS 3 days ago..
1 · Reply
bowfin2
bowfin2 Jan. 12 at 5:14 PM
$ABUS One if these mondays again ... yawn ...
0 · Reply